MANNKIND CORP Proceeds from Notes Payable
MANNKIND CORP (MNKD) reported Proceeds from Notes Payable of $70.05 million for the 12-month period ending 2019-12-31, per its 10-K filed 2021-02-25.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2021-02-25
- MANNKIND CORP proceeds from notes payable for the quarter ending 2019-12-31 was $0.00.
- MANNKIND CORP proceeds from notes payable for fiscal 2019 was $70.05M.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month | Proceeds from Notes Payable 244 month | Proceeds from Notes Payable 247 month | Proceeds from Notes Payable 250 month | Proceeds from Notes Payable 253 month | Proceeds from Notes Payable 256 month | Proceeds from Notes Payable 259 month | Proceeds from Notes Payable 263 month | Proceeds from Notes Payable 265 month | Proceeds from Notes Payable 268 month | Proceeds from Notes Payable 271 month | Proceeds from Notes Payable 275 month | Proceeds from Notes Payable 277 month | Proceeds from Notes Payable 280 month | Proceeds from Notes Payable 283 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $70.05M 10-K · filed 2021-02-25 | |||||||||||||||
| 2019-09-30 | $70.05M 10-Q · filed 2020-11-04 | ||||||||||||||||
| 2014-09-30 | $3.46M 10-Q · filed 2014-11-10 | ||||||||||||||||
| 2014-06-30 | $3.46M 10-Q · filed 2014-08-11 | ||||||||||||||||
| 2014-03-31 | $3.46M 10-Q · filed 2014-05-12 | ||||||||||||||||
| 2013-12-31 | $3.46M 10-K · filed 2014-03-03 | ||||||||||||||||
| 2013-09-30 | $3.46M 10-Q · filed 2013-11-12 | ||||||||||||||||
| 2013-06-30 | $3.46M 10-Q · filed 2013-08-09 | ||||||||||||||||
| 2013-03-31 | $3.46M 10-Q · filed 2013-05-10 | ||||||||||||||||
| 2012-12-31 | $3.46M 10-K · filed 2013-03-18 | ||||||||||||||||
| 2012-09-30 | $3.46M 10-Q · filed 2012-11-09 | ||||||||||||||||
| 2012-06-30 | $3.46M 10-Q · filed 2012-08-09 | ||||||||||||||||
| 2012-03-31 | $3.46M 10-Q · filed 2012-05-10 | ||||||||||||||||
| 2011-12-31 | $3.46M 10-K · filed 2012-03-15 | ||||||||||||||||
| 2011-09-30 | $3.46M 10-Q · filed 2011-11-04 | ||||||||||||||||
| 2011-06-30 | $3.46M 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |